Nasdaq btai.

NEW HAVEN, Conn., May 16, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...BioXcel Therapeutics, Inc. BTAI is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience.BioXcel Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 5,080,000 shares, a decrease of 12.6% from the previous total of 5,810,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a …Find the latest SEC Filings data for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.

BioXcel Therapeutics (NASDAQ:BTAI) stock is rocketing higher on Wednesday after the biopharmaceutical company announced results from an audit of its Tranquility II clinical trial.. According to a ...Jul 5, 2023 · Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in BioXcel Therapeutics Inc (Symbol: BTAI), where a total of 14,591 contracts have traded ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) issued its earnings results on Monday, August, 14th. The company reported ($1.83) earnings per share for the quarter, …Find the latest Institutional Holdings data for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.

BTAI STOCK Price - BioXcel Therapeutics Inc NASDAQ USA Technical Analysis, Forecast, Important Levels, Latest News, Interactive Charts.View real-time BTAI stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ... NEW HAVEN, Conn., May 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...Allogene Therapeutics (NASDAQ:) is a clinical-stage biotech firm specializing in developing allogeneic T cell cancer treatment therapies. Around 67.4% of ALLO’s share count consists of publicly ...Discover historical prices for BTAI stock on Yahoo Finance. View daily, weekly or monthly format back to when BioXcel Therapeutics, Inc. stock was issued. ... Nasdaq Futures 15,961.50-47.25 (-0.30 ...

NEW HAVEN, Conn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...

NEW HAVEN, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...

Apr 28, 2023 · 586,279. 6.770742. Back to BTAI Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end ... Nov 24, 2023 · BioXcel Therapeutics (NASDAQ: BTAI) is another of the low-float, heavily-shorted penny stocks in the biotech space. Based on its “about us” page, BioXcel is riding the coattails of “AI Mania ... This forecast implies upside of 128%. Thus, BTAI could be one of the best short-squeeze stocks. Aravive (ARAV) Source: Epic Cure / Shutterstock. Hailing from Houston, Texas, Aravive (NASDAQ:ARAV) ...On November 17, 2023, BTAI’s average trading volume was 3.13M shares. BTAI) stock’s latest price update. The stock of BioXcel Therapeutics Inc (NASDAQ: BTAI) has decreased by -0.47 when compared to last closing price of 4.25.Despite this, the company has seen a loss of -18.18% in its stock price over the last five trading days.BioXcel Therapeutics Inc (NASDAQ: BTAI) announced alignment with the FDA's recommendation for a Phase 3 trial in the TRANQUILITY program of BXCL501 for acute treatment of agitation associated Nov 26, 2023 · Allogene Therapeutics (NASDAQ:) is a clinical-stage biotech firm specializing in developing allogeneic T cell cancer treatment therapies. Around 67.4% of ALLO’s share count consists of publicly ... NEW HAVEN, Conn., May 16, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...

Nov 20, 2023 · BioXcel Therapeutics Inc (NASDAQ:BTAI) trade information. Instantly BTAI was in red as seen at the end of in last trading. With action -20.12%, the performance over the past five days has been red. The drop to weekly highs of 5.62 on Friday, 11/17/23 subtracted -2.82% to the stock’s daily price. For more information, call Reed Kathrein at 844-916-0895 or email [email protected]. Hagens Berman is a global plaintiffs’ rights complex litigation law firm focusing on corporate accountability ...The latest price target for . BioXcel Therapeutics (NASDAQ: BTAI) was reported by HC Wainwright & Co. on Wednesday, November 15, 2023.The analyst firm set a price target for 11.00 expecting BTAI ...markets.businessinsider.com - November 30 at 12:41 AM. BioXcel Therapeutics (BTAI) Price Target Increased by 5.88% to 14.28. msn.com - November 27 at 9:35 AM. BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives $23.88 Average PT from Analysts. americanbankingnews.com - November 24 at 2:22 AM.BTAI stock is down 57.2% as of Thursday morning. That comes as some 3.2 million shares change hands, as compared to its daily average trading volume of about 549,000 shares. Investors seeking out ...NEW HAVEN, Conn., Feb. 23, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...

View real-time BTAI stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...

SAN FRANCISCO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now. Class Period ...The average one-year price target for BioXcel Therapeutics (NASDAQ:BTAI) has been revised to 14.28 / share. This is an increase of 5.88% from the prior estimate of 13.49 dated October 31, 2023.The 5 analysts offering 12-month price forecasts for BioXcel Therapeutics Inc have a median target of 11.00, with a high estimate of 18.00 and a low estimate of 4.00. The median estimate ...4 Jul 2023 ... Fintel reports that on July 3, 2023, HC Wainwright & Co. maintained coverage of BioXcel Therapeutics (NASDAQ:BTAI) with a Buy ...BioXcel Therapeutics Inc (NASDAQ:BTAI) BioXcel Therapeutics Inc. 4.13. Delayed Data. As of Nov 17. -0.12 / -2.82%. Today’s Change. 2.23.BioXcel Therapeutics, Inc. (BTAI.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock BioXcel Therapeutics, ...According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...NEW HAVEN, Conn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...NEW HAVEN, Conn., March 15, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...See the latest BioXcel Therapeutics Inc stock price (BTAI:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Nov 6, 2023 · BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ...

About. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...

Apr 28, 2023 · 586,279. 6.770742. Back to BTAI Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end ... The public float for BTAI is 20.22M, and currently, short sellers hold a 25.11% ratio of that floaft. The average trading volume of BTAI on November 30, 2023 was 3.17M shares. BTAI) stock’s latest price update. BioXcel Therapeutics Inc (NASDAQ: BTAI)’s stock price has dropped by -0.26 in relation to previous closing price of 3.91.Shares of the commercial-stage biopharma BioXcel Therapeutics ( BTAI 16.29%) were up by 10.3% on heavy volume as of 3:29 p.m. ET Monday afternoon. The big gain came after the drugmaker reported ...BioXcel Therapeutics Inc. Follow. Share. $3.93. After Hours: $3.90. (0.76%) -0.030. Closed: Nov 24, 4:39:38 PM GMT-5 · USD · NASDAQ · Disclaimer. search Compare to.The average one-year price target for BioXcel Therapeutics (NASDAQ:BTAI) has been revised to 14.28 / share. This is an increase of 5.88% from the prior estimate of 13.49 …Apr 28, 2023 · 586,279. 6.770742. Back to BTAI Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end ... SAN FRANCISCO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now. Class Period ...BioXcel reported a net loss of $21.1 million for the fourth quarter of 2020, compared to a net loss of $8.3 million for the same period in 2019. For the full year, BioXcel reported a net loss of ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI) to host virtual Neuroscience R&D Day to discuss BXCL502, a potential treatment for chronic agitation in dementia, along with other emerging pipeline candidates. Dr. Jeffrey Cummings and Dr. Sandra Comer to discuss agitation relief in Alzheimer’s disease and BXCL501 as a potential treatment for opioid …

Over the past 3 months, 10 analysts have published their opinion on BioXcel Therapeutics (NASDAQ:BTAI) stock. These analysts are typically employed by large Wall Street banks and tasked with ...BTAI's recent financials show a net loss of $53.5MM for 2Q23, with a cash reserve expected to last until mid-2024. Strategic financing negotiations are underway. We maintain a hold rating on ...NEW HAVEN, Conn., June 23, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...SAN FRANCISCO, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges BioXcel Therapeutics, Inc. (NASDAQ: BTAI) investors who suffered substantial losses to submit your losses now. Class Period ...Instagram:https://instagram. nasdaq admadollar store stocksonline brokers for penny stockscrm earnings report Apr 5, 2023 · The FDA-approved Igalmi from BioXcel Therapeutics (NASDAQ:BTAI) for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults has garnered attention. NEW HAVEN, Conn., Sept. 23, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ... invesco global opportunities fundbioxcel BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ... forex.com reviews 14 Aug 2023 ... Shares of the biopharmaceutical company, BioXcel Therapeutics (NASDAQ: BTAI) tanked at the time of writing on Monday after the company ...BioXcel Therapeutics, Inc. Common Stock (BTAI) Nasdaq Listed. DATA AS OF Nov 12, 2021. 0. Add to Watchlist.